Chester County News and Community Website
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), headquartered in Wayne, PA, is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) said it will take center stage at two major healthcare investor conferences in February, giving Wall Street and industry watchers a fresh …
Aclaris Lines Up February Spotlight at Major Biotech Investor Conferences Read More WAYNE, PA — Aclaris Therapeutics, Inc. (Nasdaq: ACRS) reported striking preclinical results for its experimental oral drug ATI-2138, showing rapid, near-complete, and sustained hair regrowth in a severe mouse model …
Experimental Hair-Loss Drug Sparks Rapid Regrowth in Severe Alopecia Study Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) said it has launched a placebo-controlled Phase 1b proof-of-concept trial of ATI-052, an experimental bispecific antibody aimed at treating atopic dermatitis, marking …
Aclaris Pushes New Antibody Into Skin Disease Trial, Eyes Asthma Next Read More WAYNE, PA — Aclaris Therapeutics Inc. (NASDAQ: ACRS) said positive interim data from its first-in-human study of ATI-052 are accelerating the experimental drug’s push toward later-stage trials, signaling what the …
Early Trial Data Puts Aclaris’ ATI-052 on Fast Track Toward Bigger Bets Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) said it has been added to the Nasdaq Biotechnology Index, a move that places the clinical-stage biopharmaceutical company among a select group …
Aclaris Joins Nasdaq Biotech Index, Marking Milestone for Clinical-Stage Firm Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) reported third-quarter 2025 financial results and outlined continued progress across its expanding immuno-inflammatory pipeline, emphasizing execution in both oral kinase inhibitors and …
Aclaris Therapeutics Advances Immuno-Inflammatory Pipeline, Targets Four Clinical Programs in 2026 Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) will showcase its latest developments in immuno-inflammatory research at three prominent healthcare investment conferences in November, reflecting growing investor interest in the …
Aclaris to Spotlight Immuno-Inflammatory Pipeline at Major Healthcare Conferences Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced it will hold its 2025 R&D Day in Midtown, New York, on Tuesday, October 14, at 8:00 a.m. ET. The event …
Aclaris to Host 2025 R&D Day in New York to Spotlight Immuno-Inflammatory Pipeline Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced that new findings from its Phase 2a trial of ATI-2138, an investigational oral therapy for moderate-to-severe atopic dermatitis, will be featured …
Aclaris Therapeutics to Present New Data on Atopic Dermatitis Drug at EADV Congress Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced that it will participate in two upcoming healthcare conferences in September to highlight corporate updates and its development strategy.
Aclaris Therapeutics to Present at Two Investor Conferences in September Read More